Skip to main content

Table 1 Baseline Characteristics

From: The role of Asprosin in patients with dilated cardiomyopathy

Variable All patients (n = 50) Asprosin P value
Low group (n = 25) High group (n = 25)
Age, y 55 ± 10 (35–78) 55 ± 11 (35–78) 54 ± 9 (36–71) 0.98
Female gender, n (%) 7 (14.0%) 4 (16.0%) 3 (12.0%) > 0.99
Body mass index, kg/m2 25.8 ± 4.3 25.2 ± 4.6 26.4 ± 4.1 0.44
Hypertension, n (%) 14 (28.0%) 6 (24.0%) 8 (32.0%) 0.75
Diabetes mellitus, n (%) 12 (24.0%) 6 (24.0%) 6 (24.0%) > 0.99
Systolic blood pressure, mmHg 115 ± 21 112 ± 22 118 ± 19 0.25
Heart rate, bpm 80 ± 16 82 ± 16 79 ± 18 0.47
NYHA class III or IV, n (%) 15 (30.0%) 7 (28.0%) 8 (32.0%) > 0.99
COPD, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) > 0.99
Atrial fibrillation, n (%) 17 (34.0%) 8 (32.0%) 9 (36.0%) > 0.99
LV mass index, g/m2 344.9 ± 104.6 358.0 ± 110.7 331.8 ± 98.6 0.46
LV end-diastolic volume index, mL/m2 248.9 ± 74.9 248.1 ± 81.3 249.7 ± 69.7 0.99
LV ejection fraction, % 27.1 ± 9.9 26.5 ± 10.7 27.7 ± 9.2 0.63
Mitral E/A ratio 1.4 ± 0.9 1.4 ± 0.7 1.4 ± 1.1 0.85
ACEI/ARB, n (%) 44 (88.0%) 23 (92.0%) 21 (84.0%) 0.67
Beta-blockers, n (%) 42 (84.0%) 21 (84.0%) 21 (84.0%) > 0.99
Spironolactone, n (%) 30 (60.0%) 15 (60.0%) 15 (60.0%) > 0.99
Loop diuretics, n (%) 36 (72.0%) 19 (76.0%) 17 (68.0%) 0.75
Digoxin, n (%) 21 (42.0%) 10 (40.0%) 11 (44.0%) > 0.99
BNP, pg/mL 1073 ± 1199 1208 ± 1370 955 ± 1046 0.74
eGFR, mL/min/1.73 m2 75.4 ± 24.5 77.1 ± 22.9 73.7 ± 26.3 0.73
Creatinine, mg/dL 1.5 ± 1.8 1.7 ± 2.4 1.2 ± 0.7 0.94
Cholesterol, mg/dL 156.4 ± 35.0 147.4 ± 31.3 165.5 ± 36.8 0.09
Sugar, mg/dL 103.8 ± 24.9 99.6 ± 16.7 108.2 ± 31.1 0.43
HbA1C, % 6.2 ± 1.1 6.1 ± 1.0 6.4 ± 1.3 0.54
  1. ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, BNP B-type natriuretic peptide, COPD chronic obstructive pulmonary disease, eGFR estimated glomerulus filtration rate, HbA1C glycohemoglobin, LV left ventricle, NYHA New York Heart Association